Influence of Interleukin-6 (174G/C) Gene Polymorphism on Obesity in Egyptian Children

Ola M. Ibrahim1, Azza A. Gabre1, Sara F. Sallam1, Inas R. El-Alameey1, Rania N. Sabry1, Essam M. Galal1, Sawsan M. Tawfik1, Waheba A. Zarouk2, Rehab M. Mosaad2, Abeer Ramadan2

1Child Health Department, Medical Division, National Research Centre, Egypt; 2Molecular Genetics & Enzymology Department, Human Genetics and Genome Research Division, National Research Centre, Egypt

Abstract

BACKGROUND: Obesity is a multi-factorial chronic disorder. A considerable number of studies have been performed to figure out whether there is an association between obesity and polymorphisms of gene IL-6 (174G/C), but the results are equivocal.

AIM: This study aimed to find out whether the IL-6 (174G/C) gene was associated with the risk of developing obesity in Egyptian children.

SUBJECTS AND METHODS: The study included 149 children and adolescents with age ranged between 9.5 – 18 years. Eighty-five of them were obese which BMI-Z score is > 2, and sixty-four children with BMI-Z-score ≤ 2 served as control group. Serum level of IL-6 and genetic analysis for IL-6 (174G/C) gene polymorphism were done.

RESULTS: Obese children had significantly higher serum levels of IL-6 as compared to those of control children (P = 0.003). A high percentage of IL-6 polymorphism GC was found in obese subjects (93.7%), while the control group had a higher percentage of IL-6 polymorphism GG (76.6%).

CONCLUSION: Our study showed that carriers of the G allele for the IL-6 (174G/C) polymorphism have higher BMI. As the G174C polymorphism is likely to affect IL-6 expression and its physiological regulation; consequently this polymorphism may affect adiposity.

Introduction

Obesity represents one of the major Public Health problems. Obese children have a shorter life expectancy by 20 years if they remain obese till young adulthood [1]. North African Countries and the region of Middle East just like the other developing countries are not spared from the issue of the world [2, 3]. Genetics, metabolic, social, cultural and environmental factors interact as different cofactors for the development of obesity. The prevalence of obesity in Egyptian children ranged from 13.5 % up to 23.7% [4–5].

Advanced knowledge of human genome variations led to identification of genes susceptible to contribute in obesity and other related diseases; meanwhile few studies focused specifically on the interactions between obesity and genetic polymorphism [6]. Interleukin-6 (IL-6) is an immune-modulator pro-inflammatory cytokine involved in the regulation of the acute phase response [7]. High IL-6 serum level was found in obese patients as well as patients suffering chronic inflammatory conditions and serum lipid concentrations abnormalities [8]. Interleukin-6 production has been shown to be significantly increased by adipose tissue in a state of obesity. The increased IL-6 levels in obese individuals may result in a state of insulin resistance and increased risk of cardiovascular complication [9].

Plasmatic levels of cytokines and its transcriptional regulation is influenced by the
polymorphisms of IL-6 (especially 174G/C) as proved in many population groups based genetic studies, that have been performed to figure out whether there is an association between obesity and IL-6 (174G/C) polymorphisms, but results were not conclusive with a lot of controversies [10-11].

Based on this; this study aimed to find out whether IL6 (174G/C) polymorphisms designated as rs1800795 as well, is associated with the risk of developing obesity in Egyptian children.

Subjects and Methods

This is a cross-sectional study that included one hundred and forty-nine children and adolescents, 71 males and 78 females. Their age ranged between 9.5 to 18 years (mean 11.72 ± 2.52 yrs). This study started by one thousand children and adolescents chosen randomly from three governmental schools at Giza. According to their anthropometric measures, it was found that one hundred and thirty were obese (BMI-Z score >2). Eighty-five of them (41 males and 44 females) were fulfilling the criteria and gave the consent to share in the study.

Exclusion criteria: factors that might lead to the misclassification of a child’s weight status, that are: (1) an acute or chronic illness affecting weight; (2) genetic conditions associated with obesity or failure to thrive; and/or (3) use of medications associated with weight gain or loss.

Inclusion criteria: apart from obesity; all obese subjects and non-obese controls were in good health. This study was a part of project that approved by the Medical Ethical Committee of the National Research Center with registration number 14046. All participants were informed about the objectives of the study and volunteered to participate and the parents of all subjects provided a written informed consent.

Anthropometric assessments

Anthropometric assessments were performed according to techniques described in the Anthropometric Standardization Reference Manual [12]. Weight was measured using a calibrated Seca scale to the nearest 0.1 kg (Seca, Hamburg, Germany), whereas height (in cm) was measured using a Seca 225 stadiometer to the nearest 0.1 cm, with the children dressed in minimal clothes and without shoes. Each measurement was taken as the mean of three consecutive readings following the recommendations of the International Biological Program [13]. Weight for height, weight for age, height for age, and BMI for age was recorded according to WHO standards using Anthro Plus software for personal computers [3]. Measurements were expressed as weight-for-age Z-score (WAZ), height for age Z-score (HAZ), and BMI Z-score (BAZ). The participants were then grouped according to the WHO Global Database on Child Growth and Malnutrition using a Z-score cut-off point [14]: Overweight and obese children with BAZ >2 and control children with BAZ ≤ 2.

Laboratory Investigations

Fasting blood sample was drawn from each participant into vacutainer tube containing EDTA as an anticoagulant. The samples were immediately transferred to the laboratory, centrifuged immediately for 10 min at 4000 and stored at -80°C.

- Serum interleukin-6 level measuring using the quantitative Enzyme-Linked Immune-Sorbent Assay (ELISA) with a commercial kit provided by DIA source, Belgium [15].

- DNA extraction: Blood samples were collected on Na2EDTA as an anticoagulant. Genomic DNA was purified from 200 μl whole blood with the QIAamp® DNA Blood Mini Kit (Qiagen) according to the Blood and Body Fluid Spin Protocol in the accompanying handbook. DNA was eluted in 200 μl elution buffer and stored at -20°C.

- Detection of IL6 (-174G/C) polymorphism: DNA was amplified with primers specific for -174G/C (rs1800795) in a 25 μl reaction mixture containing: 50 ng μL genomic DNA, ddH2O 15.7 μL, 10 x buffer 2.5 μL, dNTP (10 mmol) 0.5 μL, each of primer sequences (10 μmol) 0.5 μL, MgCl2 (25 mmol) 2 μL and 1U Taq enzyme. The PCR was performed in 30 cycles; (95°C for 30 sec, annealing at 55°C for 30 s, and extension at 72°C for 1 min), with an initial denaturation at 95°C for 5 min and a final extension at 72°C for 10 min. Followed by final extension 72°C for 5 min. All PCR products were analyzed by 2% agarose gel electrophoresis.

- Enzyme digestion: Post PCR–RFLP was done by incubating five μl of SNP-PCR product with the restriction enzyme Nla III at 37°C for 30 min. The digested SNP-PCR product was electrophoresed on 3% agarose gel [16].

Statistical analysis

The data were analyzed using statistical package for social sciences (SPSS) version 16. Results were presented as mean ± SD, except where otherwise indicated. Comparisons between groups were done by independent samples t-test. Chi-square test was used to estimate differences in qualitative variables. Pearson correlation test was used to determine the relationship between some numerical variables. For all tests, probability values (P) of less than 0.05 were regarded as statistically significant.
Results

The characteristics of the studied groups are shown in Table 1. The mean serum level of IL-6 in obese children was significantly higher as compared to those of control children (7.7 ± 0.46 pg/mL and 5.46 ± 0.40 pg/mL respectively (P = 0.003). Serum IL-6 level had a positive correlation with age (r = 0.28 and p = 0.001) and with BAZ (r = 0.188 and p = 0.03).

Table 1: Characteristics of the studied groups

| Parameter                  | Controls | Obese | P  |
|----------------------------|----------|-------|----|
| Number                     | 64       | 85    |    |
| Males: females             | 30:34    | 41:44 | ns |
| Mean age (years)           | 10.9 ± 2.3| 12.3 ± 2.4| ns |
| Z-score BMI (kg/m²)        | 0.13 ± 0.16| 2.8 ± 0.62| 0.00|
| IL-6 (pg/ml)               | 5.46 ± 0.40| 7.7 ± 0.46|    |

P value ≤ 0.05 is significant.

Result of genotyping analysis of IL6-174G/C polymorphism

The Nla III restriction enzyme digest the 500 bp applicant of the IL6-174; where G allele yielded three bands (of 264, 207 and 29bp); the C allele yielded four bands (of 264, 122, 85 and 29 bp) (Figure 1A & 1B).

A) 500 bp

B) 264 bp

Figure 1: A) Agarose gel (3%) photographs of PCR-RFLP products (amplicons digested with restriction enzymes) depicting the genotypes of IL-6 polymorphisms PCR and digestion products run on 3% agarose gel electrophoresis. Lane 1: ΦX 174 marker/Hae III digest. Lane 2: The PCR amplified product (500 bp). Lanes 3, 4, 6, and 8: G/G genotype (264, 207 and 29 bp). Lanes 5, 7, and 9: G/C genotype (264, 207 and 122 bp); B) Fig 2: PCR and digestion products run on 3% agarose gel electrophoresis. Lane 1: ΦX 174 marker / Hae III digest. Lane 2: The PCR amplified product (500 bp). Lanes 3, 4, 6, 7, 8, 9, 10, 12: G/C genotype (500, 264, 122 and 85 bp).

Table 2 shows the distribution of genotype for IL6 (-174G/C) polymorphism: The homozygote genotype (G/G) was 57.05 %, the heterozygote (G/C) 42.95 % and none of our patients was carrying the homozygote genotype (C/C).

Table 2: The frequency of genotype of IL-6 polymorphism

| Polymorphism | Frequency | Percent |
|--------------|-----------|---------|
| Heterozygous | GC        | 64      | 42.95  |
| Homozygous   | GG        | 85      | 57.05  |
| Total        |           | 149     | 100    |

Table 2 shows the distribution of genotype for IL6 (-174G/C) polymorphism: The homozygote genotype (G/G) was 57.05 %, the heterozygote (G/C) 42.95 % and none of our patients was carrying the homozygote genotype (C/C).

No significant difference in the serum level of IL-6 between subjects with IL-6 (174G/C) polymorphism and those with IL6 (174G/G) polymorphism (Table 3).

Table 3: The mean serum level of IL-6 in both groups of polymorphism

| Polymorphism | GG     | GC     | P   |
|--------------|--------|--------|-----|
| IL-6 (pg/ml) | Mean ± SD | 6.53 ± 4.97 | 6.99 ± 4.52 | ns |

Table 4 shows that the mean of BMI Z score was significantly higher in IL-6 polymorphism GC as compared to that of polymorphism GG. Our results showed that 95.3 % of IL-6 polymorphism GC was found in obese subjects as compared to 4.7 % in normal weight children.

Table 4: The mean ±SD of BMI Z-score (BAZ) in both types of IL-6 polymorphism

| Polymorphism | GG     | GC     | P   |
|--------------|--------|--------|-----|
| BMI-Z-score  | Mean ± SD | 2.76 ± 0.68 | 0.86 ± 1.6 | 0.00 |

On the other hand, 71.8 of IL-6 (174G/G) polymorphism were found in controls as compared to 28.2% in obese children (Table 5). It was noted in the results that, none of our children were carrying C/C genotyping.

Table 5: The percentage of IL-6 polymorphism in obese and control groups

| IL-6 polymorphism | Controls (%) | Obese (%) | P   |
|-------------------|--------------|-----------|-----|
| GG (n=85)         | 81           | 77.8      | 24  |
| GC (n=64)         | 3            | 4.7       | 61  |
| Total             | 149          | 100       | 95.3| 0.00 |

Discussion

This study revealed a significantly higher serum level of IL-6 in obese children as compared to those of controls. The same finding was previously reported in a study of Filippo et al. [11]. Our data showed a positive correlation of IL-6 with both age and BAZ.

These results are by the results of Diego et al. [17] and Paltoglou et al. [18]. In this work, we studied whether the IL6(174G/C) gene is associated with the risk of developing obesity in obese Egyptian children. The analysed polymorphism (174G/C) is localised in the promoter region of the IL-6 gene, where transcription factors frequently exert their functions through its influence on the energy expenditure.
The results revealed that the GG homozygote genotype is predominated in the control group (95.3 %) with a statistically significant difference compared to that of obese children (28.2 %). If we considered the GC genotypes as C carrier; so, the study showed a prevalence 71.8 % (61 of 85), of this C allele among the obese children as compared with 4.7% (3 of 64) in the normal weight children. So, the examined polymorphisms of the pro-inflammatory cytokine IL-6 (174G/C) could play a role in the regulation of body mass. According to these aspects, the results of this study seem to confirm the hypothetical relation between the IL6 (174G/C) genotype and the risk of developing obesity among Egyptian children.

Our data match and is replicated with previously published data; as some authors have investigated the relation between polymorphisms in IL-6 gene and obesity based on experimental evidence on mice suggested an influence on fat mass, fat metabolism, and body mass and on the development of obesity [19]. Zhangbin et al., [20] realized that IL-6 (174 G/C) polymorphism was also associated with obesity by covering 48 studies with outcome similar to the results in our study.

In a study of Popko et al., [21] the detected C allele in both C/C homozygotes and G/C heterozygotes of IL6 (174 G/C) gene was related to a significant increase in the sum of 10 skinfold thickness measurements in obese girls; which is consistent with the results of our study. A study enrolling Greek school children had shown an association of the IL-6 variant rs1800796 with parameters related to obesity [22]. Oana et al. [23] described the G allele at C-174 as being more common in lean subjects and observed the C allele to be associated with indices of obesity. These findings are in concordance with the results of our study, in which the GC heterozygote genotype predominated in the obese group, and the GG genotype was less pronounced in this group than in the normal weight group. In this study, none of our children was carrying C/C genotyping. This is because it is a pilot study and our sample size was small. It was previously reported by Saxena et al. [24] that CC genotype was very rare in their study.

Contrary to our findings, data reported in an Iranian study among 242 persons, sustained more frequent G alleles in the obese but was statistically insignificant [25]. Another meta-analysis didn’t find significant associations of IL6 (174G/C) genotypes with waist-to-hip ratio, waist circumference, or central obesity and did not support a role for this polymorphism in adiposity [26].

In conclusion, our study showed that carriers of the C allele for the IL-6 polymorphism G174C have higher BMI. As the G174C gene polymorphism is likely to affect IL-6 expression and its physiological regulation; consequently this polymorphism may affect adiposity and insulin sensitivity. It is recommended in future studies for the IL-6 polymorphism G174C to be done in a wider scale of children and adolescents and in different demographic areas as our study enrolled relatively small number of obese and normal children which decreased the power of the group in statistic results.

References

1. Gabbert G, Donohue M, Arnold J, Schwimmer JB. Adenovirus 36 and obesity in children and adolescents. Pediatrics. 2010; 126(4): 721-726. https://doi.org/10.1542/peds.2009-3362 PMID:20855385

2. Remla N, Hadjiij Z, Ghezzaz K, Moulesssehoul S, Aribi M. Increased gustatory response score in obesity and association levels with IL-6 and Leptin. Journal of Nutrition and Metabolism. 2016; 2016; Article ID 7924052.

3. WHO. Anthro Plus for personal computers, manual software for assessing growth of the world’s children and adolescents. Geneva: department of nutrition for health; 2009. Available at: ttp://www.who.int/growthref/tools/en

4. Badawi NES, Barakat AA, El Sherbini SA, Fawzy HM. Prevalence of overweight and obesity in primary school children in Port Said city. Egyptian Pediatric Association Gazette. 2013; 61: 31-36. https://doi.org/10.1016/j.epag.2013.04.007

5. Taha AA, Marawan HM. Socio-behavioral determinants of overweight and obesity in Egyptian primary school children. J Child Adolesc Behav. 2015; 3:236.

6. Qi L, Zhang C, van Dam RM, Hu FB. Interleukin-6 genetic variability and adiposity associations in two prospective cohorts and systematic review in 26,944 individuals. J Clin Endocrinol Metab. 2007; 92(9): 3618–3625. https://doi.org/10.1210/jc.2007-0877 PMID:17623760

7. Senn JJ, Klover Pj, Nowaki A, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA. Suppressor of cytokine signaling-3 (socs-3), a potential mediator for interleukin-6 dependent insulin resistance in hepatocytes. J Biol Chem. 2003;278(16) :13740-6 https://doi.org/10.1074/jbc.M210669200 PMID:12560330

8. Galcheva S V, Violeta M L, Yoto T Y, Sergio B Maria E S. Circulating proinflammatory peptides related to abdominal adiposity and cardiometabolic risk factors in healthy prepubertal children. Eur J Endocrinol. 2011; 164(4):553-8. https://doi.org/10.1530/EJE-10-1124 PMID:21224406

9. Raynald T, Sarah MW, Hesti L. Interleukin-6 and insulin resistance in obese adolescents. Paediatr Indones. 2013;53(5):268-72. https://doi.org/10.14238/pj53.5.2013.06

10. Popko K, Gorska E, Pryzak B, Telmaszczyk-Emmel A, Wisniewska A, Majcher A, Wasik M, Demkow U. Influence of proinflammatory cytokine gene polymorphism on childhood obesity. Eur J Med Res. 2009; 14(Suppl4):59–62. PMID:20156727

PMCID:PMC3521345

11. Filippo DeG, Rendina D, Moccia F., Rocco V., Campanozzi A. Interleukin-6, Soluble interleukin-6 receptor/interleukin-6 complex and insulin resistance in obese children and adolescents. Journal of Endocrinological Investigation. 2015; 38 (3) 339–343. https://doi.org/10.1530/EJE-14-0176-4 PMID:25245339

12. Lohman TG, Roche AF, Martorell R. Anthropometric standardization reference manual. Champaign, IL: Human Kinetics Publishers, 1988. PMCID:PMC279682

13. Tanner JM, Herraux J, Jarman S, Weiner JS, Laurie JA. Growth, and physique studies. Human biology: a guidance to fields methods. In: WeinerJS, Laurie SA, editors. London: Blackwell Scientific Publications, 1969:273–275.

14. WHO/EMRO: Regional data on non-communicable diseases risk factors World Health Organization, Regional Office of East
Open Access Maced J Med Sci. 5

Ibrahim et al. Interleukin-6 (174G/C) Gene Polymorphism on Obesity in Egyptian Children

Mediterranean. Non-Communicable diseases. Website: http://www.emr.who.int.ncd. Accessed April 2010.

15. DIA source IL-6 EASIA Kit. Catalogue No: KAP1261. DIA source Immuno Assays S.A Rue Du Bosquet, 2, B-1348-Louvain-La-Neuve, Belgium.

16. Martinez JC, Etxagibel A, Calleja SC. Saez-torres C, M. Sedeno M, Julia R, Muncunill J, Matamoros N, Gaya A. Allelic frequencies of polymorphic variants of cytokine genes (IL1A, IL1B, IL1RN, IL6, IL10, IL12p40, and IFNG) in a Spanish population. Immunologia. 2002; 21(2):76-86.

17. Diego Y, Joan V, Rosangela T, Montse B, Miquel G, Ana M, Antonio C. Interleukin-6 in obese children and adolescents with and without glucose intolerance. Diabetes Care. 2007; 30 (7): 1892-1894. https://doi.org/10.2337/dc06-2289 PMid:17416792

18. Pattoglou G, Maria S, George V, Alexandra A, Athanasios C. The Morbid connection among obesity, aseptic inflammation, pro-oxidation and markers of insulin resistance in pre- and early-pubertal boys before and after an acute bout of treadmill exercise. Endocrine Society's 97th. Annual Meeting and Expo, March 5–8: San Diego, 2015

19. Chida D, Osaka T, Hashimoto O, Iwakura Y. Combined interleukin-6 and interleukin-1 deficiency causes obesity in young mice. Diabetes. 2006; 55:971–977. https://doi.org/10.2337/diabetes.55.04.06.db05-1250 PMid:16567518

20. Zhangbin Y, Shuping H, Xingguo C, Chun Z, Xuejie W, Xirong G. Genetic polymorphisms in adipokine genes and the risk of obesity: a systematic review and metaanalysis. Obesity. 2011; 20:396–406.

21. Popko K, Gorska E, Pyrzak B, Telmasczyk-Emmel A, Wisniewska A, Majcher A, Wasik M, Demkow U. Influence of proinflammatory cytokine gene polymorphism on childhood obesity. Eur J Med Res. 2009; 14(Suppl4):59–62. PMid:20156727 PMCID:PMC321345

22. Dedoussi GVZ, ManiosY, Choumerianou DM, Yiannakouris N, Panagiotakos DB, Skenderi K and Zampelas A. The IL-6 Gene G-174C polymorphism related to health indices in Greek primary school children. Obes Res. 2004; 12: 1037-1041. https://doi.org/10.1038/oby.2004.130 PMid:15292466

23. Oana M, Claudia B, Carmen D, Maria P, Septimiu V, Claudiu M. The role of IL-6 572 C/G, 190 C/T, and 174 G/C gene polymorphisms in children's obesity. European Journal of Pediatrics. 2014;173 (10) 1285–1296. https://doi.org/10.1007/s00431-014-2315-5 PMid:24740880

24. Saxena M, Agrawal C, Srivastava N, and Banerjee M. Interleukin-6 (IL-6)597 A/G (rs1800797) & 174 G/C (rs1800795) gene polymorphisms in type 2 diabetes. Indian J Med Res. 2014; 140 (1): 60–68. PMid:25222779 PMCID:PMC4181162

25. Rostami F, Haj Hosseini R, Sharifi K, Daneshpour M, Azizi F, and Hedayati M. Association of G174C polymorphism of the interleukin-6 Gene promoter with obesity in Iranian population. World Acad Sci Technol. 2010; 45:99–102.

26. Toderdi P, Klinger E, Ferreira M, Reuter C, Burgos M, Possuelo L, Valim A. Association of IL-6 and CRP gene polymorphisms with obesity and metabolic disorders in children and adolescents. An Acad Bras Cienc. 2015;87 (2) 1678-2690. https://doi.org/10.1590/0001-3765201520140364 PMid:25993353